Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Tommy Gambles

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Journal of Controlled Release : Official Journal of the Controlled Release Society|April 30, 2023
Multi-targeted immunotherapeutics to treat B cell malignanciesM Tommy Gambles, Jiyuan Yang, Jindřich Kopeček
Macromolecular Bioscience|October 15, 2023
Obinutuzumab-Based Drug-Free Macromolecular Therapeutics Synergizes with Topoisomerase InhibitorsM Tommy Gambles, Douglas Sborov, Paul Shami, et al.
Molecules (Basel, Switzerland)|August 7, 2021
Crosslinking of CD38 Receptors Triggers Apoptosis of Malignant B CellsM Tommy Gambles, Jiahui Li, Jiawei Wang, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|August 29, 2022
Simultaneous crosslinking of CD20 and CD38 receptors by drug-free macromolecular therapeutics enhances B cell apoptosis in vitro and in vivoM Tommy Gambles, Jiahui Li, D Christopher Radford, et al.
ACS Nano|August 16, 2024
Multiantigen T-Cell Hybridizers: A Two-Component T-Cell-Activating TherapyM Tommy Gambles, Shannuo Li, Isaac Kendell, et al.
Drug Delivery and Translational Research|May 27, 2024
Human serum albumin-based drug-free macromolecular therapeutics induce apoptosis in chronic lymphocytic leukemia patient cells by crosslinking of CD20 and/or CD38 receptorsJiahui Li, M Tommy Gambles, Brandt Jones, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|May 2, 2025
Two-component T-cell immunotherapy enables antigen pre-targeting to reduce cytokine release without forfeiting efficacyM Tommy Gambles, Isaac Kendell, Jiahui Li, et al.
Communications Biology|July 13, 2026
Computer-guided dosing of multi-specific T-cell engagersIsaac Kendell, Richard McShinsky, Katarzyna Modzelewska, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Journal of Controlled Release : Official Journal of the Controlled Release Society|April 30, 2023
Multi-targeted immunotherapeutics to treat B cell malignanciesM Tommy Gambles, Jiyuan Yang, Jindřich Kopeček
Macromolecular Bioscience|October 15, 2023
Obinutuzumab-Based Drug-Free Macromolecular Therapeutics Synergizes with Topoisomerase InhibitorsM Tommy Gambles, Douglas Sborov, Paul Shami, et al.
Molecules (Basel, Switzerland)|August 7, 2021
Crosslinking of CD38 Receptors Triggers Apoptosis of Malignant B CellsM Tommy Gambles, Jiahui Li, Jiawei Wang, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|August 29, 2022
Simultaneous crosslinking of CD20 and CD38 receptors by drug-free macromolecular therapeutics enhances B cell apoptosis in vitro and in vivoM Tommy Gambles, Jiahui Li, D Christopher Radford, et al.
ACS Nano|August 16, 2024
Multiantigen T-Cell Hybridizers: A Two-Component T-Cell-Activating TherapyM Tommy Gambles, Shannuo Li, Isaac Kendell, et al.
Drug Delivery and Translational Research|May 27, 2024
Human serum albumin-based drug-free macromolecular therapeutics induce apoptosis in chronic lymphocytic leukemia patient cells by crosslinking of CD20 and/or CD38 receptorsJiahui Li, M Tommy Gambles, Brandt Jones, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|May 2, 2025
Two-component T-cell immunotherapy enables antigen pre-targeting to reduce cytokine release without forfeiting efficacyM Tommy Gambles, Isaac Kendell, Jiahui Li, et al.
Communications Biology|July 13, 2026
Computer-guided dosing of multi-specific T-cell engagersIsaac Kendell, Richard McShinsky, Katarzyna Modzelewska, et al.
Pageof 1